Belpointe Asset Management LLC Buys 6,088 Shares of Medtronic PLC $MDT

Belpointe Asset Management LLC boosted its stake in Medtronic PLC (NYSE:MDT) by 57.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,712 shares of the medical technology company’s stock after purchasing an additional 6,088 shares during the period. Belpointe Asset Management LLC’s holdings in Medtronic were worth $1,605,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Corundum Trust Company INC bought a new position in shares of Medtronic in the third quarter worth approximately $27,000. Lodestone Wealth Management LLC bought a new stake in Medtronic during the 4th quarter valued at $27,000. Board of the Pension Protection Fund bought a new stake in Medtronic during the 4th quarter valued at $29,000. GoalVest Advisory LLC purchased a new stake in Medtronic during the 4th quarter valued at $29,000. Finally, Valley Wealth Managers Inc. purchased a new stake in Medtronic during the 3rd quarter valued at $29,000. Institutional investors own 82.06% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on MDT. Stifel Nicolaus decreased their price objective on shares of Medtronic from $105.00 to $95.00 and set a “hold” rating on the stock in a research report on Monday, April 6th. William Blair upgraded shares of Medtronic from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 6th. Barclays raised their target price on Medtronic from $118.00 to $120.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 1st. Weiss Ratings restated a “buy (b-)” rating on shares of Medtronic in a report on Monday, December 29th. Finally, UBS Group reaffirmed a “neutral” rating and set a $104.00 price target on shares of Medtronic in a research report on Wednesday, February 4th. Sixteen analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $109.25.

Medtronic Stock Down 3.2%

MDT stock opened at $82.25 on Wednesday. The business has a 50 day moving average of $90.80 and a 200 day moving average of $95.53. The firm has a market cap of $105.60 billion, a PE ratio of 22.91, a price-to-earnings-growth ratio of 2.21 and a beta of 0.75. Medtronic PLC has a twelve month low of $79.93 and a twelve month high of $106.33. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business had revenue of $9.02 billion for the quarter, compared to the consensus estimate of $8.89 billion. During the same period in the previous year, the company posted $1.38 earnings per share. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts forecast that Medtronic PLC will post 5.57 EPS for the current fiscal year.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, April 17th. Investors of record on Friday, March 27th were given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 3.5%. The ex-dividend date of this dividend was Friday, March 27th. Medtronic’s dividend payout ratio is 79.11%.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic completed the acquisition of CathWorks for ~$585M, expanding its diagnostics/therapy footprint in coronary disease — a strategic bolt-on that management expects to be neutral to accretive over time. Medtronic completes acquisition of CathWorks
• Positive Sentiment: Led a $100M strategic investment in Pulnovo Medical and signed a commercial agreement — expands Medtronic’s pipeline into pulmonary hypertension and heart‑failure therapies and creates near‑term commercial synergies. Medtronic leads $100M investment in Pulnovo Medical
• Positive Sentiment: Announced a digital integration with GE HealthCare linking Stealth AXiS navigation and bkActiv intraoperative ultrasound — a product development likely to strengthen Medtronic’s neurosurgery offering and surgeon workflow value. Medtronic And GE HealthCare Tie Neurosurgical Imaging Upgrade To MDT Valuation
• Neutral Sentiment: Industry market reports (wearable injectors) name Medtronic among key players — underscores long‑term market opportunities in home care but is not an immediate earnings driver. Wearable Injectors Market Report 2026
• Neutral Sentiment: Wall Street analyst pieces remain broadly positive on MDT; analysts’ optimism can support the stock but is mixed in its market impact. Is Medtronic (MDT) a Buy as Wall Street Analysts Look Optimistic?
• Negative Sentiment: A market/technical story: coverage notes MDT is falling more than the broader market with elevated volume, trading near its 52-week low and below its 50-/200‑day moving averages — technical selling and sector rotation likely amplified the drop. Medtronic (MDT) Sees a More Significant Dip Than Broader Market
• Negative Sentiment: Strong earnings from a competitor, Intuitive Surgical, highlight mixed investor reactions in the med‑tech space — beats don’t always spark rallies and may shift investor focus across names, adding short-term volatility. Intuitive Surgical Earnings Show Big Beats Don’t Always Spark Stock Rallies

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the sale, the executive vice president directly owned 32,768 shares in the company, valued at approximately $3,201,761.28. This trade represents a 61.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.26% of the company’s stock.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).